Endovascular simulator for aortic aneurysms

心血管疾病是世界上导致死亡的主要原因。根据美国心脏协会的数据，超过8500万美国人患有心血管疾病，2011年的总治疗支出超过3200亿美元，预计到2030年将达到1208亿美元。主动脉病变如夹层和动脉瘤是一类特别新兴的心血管疾病。开放手术是目前治疗胸主动脉夹层的金标准。然而，支架植入术是治疗开放性手术高风险患者的潜在选择之一。各种血流动力学参数被怀疑是与动脉瘤发生和生长有关的主要力学因素。Vivitro Labs Inc.是一家行业领先的心血管检测设备及相关实验室检测公司。服务包括用于向FDA等监管机构提交的心脏器械的流体动力学性能评估。ViVitro的脉搏复制器是世界上应用最广泛的心脏模拟器。该公司的问题是扩大心脏模拟器的适用性，以模拟支架植入治疗前后的下降主动脉瘤。本研究的目的是探讨ViVitro的模拟器在支架植入术前后对主动脉瘤的适用性。

Cardiovascular disease is the leading cause of death in the world. According to the American HeartAssociation, more than 85 million Americans suffer from cardiovascular disease with the total treatmentspending exceeding $320B in 2011 and expected to reach $1,208B in 2030. Aortic pathologies such asdissection and aneurysm represent a particularly emergent class of cardiovascular diseases. Open surgicalprocedure is the current gold standard for treating thoracic aortic dissection. However, the stent graftimplantation is one of the potential alternatives for treating patients at high risk for an open surgical procedure.Various hemodynamic parameters are suspected to be major mechanical factors related to the genesis andaneurysm growth.Vivitro Labs Inc. is an industry-leading cardiovascular test equipment and related laboratory testing company.Services include the assessment of hydrodynamic performance of cardio devices which are used for submissionwith regulatory bodies such as the FDA. ViVitro's pulse duplicator is the most widely used heart simulator inthe world. The company's problem is to broaden the suitability of the heart simulator to simulate a descendingaortic aneurysm before and after treatment by the stent graft implantation. The objective of this study is toinvestigate the suitability of the ViVitro's simulator for aortic aneurysm before and after stent graftimplantation.